China NMPA approves Tyvyt in combo with chemotherapy to treat esophageal squamous cell carcinoma
By, Admin1 min read
Share
Innovent Biologics, Inc. (Innovent), a world-class biopharmaceutical company, and Eli Lilly and Company announced that the Center for Drug Evaluation (CDE) of China
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
